Carcinoma, Non-Small-Cell Lung, Lymphoma, Large-Cell, Anaplastic
Conditions
Brief summary
The purpose of this study is 2-fold: initially, in the dose escalation phase, the goal is to determine the safety profile of orally administered brigatinib, including: the maximum tolerated dose (MTD), dose limiting toxicities (DLTs), recommended phase 2 dose (RP2D), and pharmacokinetic (PK) profile. Then, once the RP2D is established, an expansion phase will assess the preliminary anti-tumor activity of brigatinib, both in non-small cell lung cancer (NSCLC) with ALK gene rearrangement (including participants with active brain metastases) or mutated EGFR, and in other cancers with abnormal targets against which brigatinib is active.
Detailed description
The drug being tested in this study is called brigatinib (AP26113). Brigatinib is being tested to treat people with NSCLC. This study will look at the safety, tolerability and efficacy of brigatinib. The study enrolled 137 patients. Participants were assigned to one of the following treatment groups: * Brigatinib 30 mg once daily (QD)/60 mg QD * Brigatinib 90 mg QD * Brigatinib 120 mg QD/60 mg twice daily (BID) * Brigatinib 90 mg QD-180 mg QD * Brigatinib 180 mg QD/90 mg BID * Brigatinib 240 mg QD/120 mg BID/300 mg QD This multi-center trial will be conducted worldwide. The overall expected time to participate in this study is approximately 4 years. Participants will make multiple visits to the clinic, and 30 days after the End-of-Treatment visit. Follow-up is intended to continue for at least 2 years after the initial dose.
Interventions
DRUGBrigatinib
Brigatinib tablets and capsules.
Sponsors
Ariad Pharmaceuticals
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
General Eligibility Criteria 1. All participants must have tumor tissue available for analysis. If sufficient tissue is not available, participants must undergo a biopsy to obtain adequate samples. For participants in expansion cohorts 2, 3 and 5, for whom failure of prior therapy is specified (crizotinib for cohorts 2 and 5, one epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) for cohort 3), tumor tissue must be available following failure of the prior therapy. 2. Must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST). 3. Male or female participants ≥ 18 years old. 4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. 5. Minimum life expectancy of 3 months or more. 6. Adequate renal and hepatic function. 7. Adequate bone marrow function. 8. Normal QT interval on screening electrocardiogram (ECG) evaluation. 9. For females of childbearing potential, a negative pregnancy test must be documented prior to enrollment. 10. Female participants who are of childbearing potential and fertile male participants must agree to use an effective form of contraception with their sexual partners throughout study participation. 11. Signed and dated informed consent indicating that the participant has been informed of all pertinent aspects of the study. 12. Willingness and ability to comply with scheduled visits and study procedures. Cohort-specific Eligibility Criteria PART 1: Dose Escalation Phase: 1. Histologically confirmed advanced malignancies. All histologies except leukemia; 2. Refractory to available therapies or for whom no standard or available curative treatments exist; 3. Tumor tissue available for analysis. PART 2: Expansion cohorts (5 additional cohorts): 1\. Expansion cohort 1: Non-small cell lung cancer (NSCLC) participants whose tumors exhibit anaplastic lymphoma kinase (ALK) rearrangements and who have not been treated with previous ALK inhibitors. i. Histologically or cytologically confirmed NSCLC; ii. Tumor tissue available for analysis (see General Eligibility Criterion 1; iii. History of ALK rearrangement by fluorescence in situ hybridization (FISH); iv. No prior ALK inhibitor therapy; 2. Expansion cohort 2: NSCLC participants whose tumors exhibit ALK rearrangements and who are resistant to crizotinib: i. Histologically or cytologically confirmed NSCLC; ii. Tumor tissue available for analysis (see General Eligibility Criterion 1); iii. History of ALK rearrangement by FISH; iv. Resistant to crizotinib (and have not received any other prior ALK inhibitor therapy); 3. Expansion cohort 3: NSCLC participants whose tumors exhibit an epidermal growth factor receptor EGFR-T790M mutation and who are resistant to 1 prior EGFR TKI: i. Histologically or cytologically confirmed NSCLC ii. Previous treatment with only 1 EGFR TKI for which the last administration was within 30 days of the initiation of brigatinib; iii. Documented evidence of an EGFR-T790M mutation following disease progression on the most recent EGFR TKI therapy; iv. No intervening systemic therapy between cessation of the EGFR TKI and initiating brigatinib; v. Tumor tissue available for analysis (see General Eligibility Criterion 1). 4. Expansion cohort 4: Participants with any cancers with abnormalities in ALK or other brigatinib targets. Examples include, but are not limited to, anaplastic large cell lymphoma (ALCL), diffuse large-cell lymphoma (DLCL), inflammatory myofibroblastic tumors (IMT), and other cancers with ALK abnormalities, or tumors with ROS1 fusions: i. Histologically confirmed lymphomas and other cancers, with the exception of leukemias; ii. Tumor tissue available for analysis (see General Eligibility Criterion 1). 5. Expansion Cohort 5: NSCLC participants whose tumors exhibit ALK rearrangements and who have active, measurable brain metastases: i. Histologically or cytologically confirmed NSCLC: ii. Tumor tissue available for analysis (see General Eligibility Criterion 1); iii. History of ALK rearrangement by FISH; iv. Either crizotinib naive or resistant; v. Have at least one measurable brain lesion (≥ 10 mm by contrast enhanced, T1 weighted magnetic resonance imaging \[cMRI\]). Previously treated brain lesions by stereotactic radiosurgery (SRS) or surgical resection should not be included as a target or non-target lesion; vi. Previously untreated brain metastases with radiologically documented new or progressing brain lesions. Unequivocal progression of previously treated lesions (non-SRS and non-surgically treated lesions) at least 3 months after the last treatment; vii. Neurologically stable. Participants must be on a stable or deceasing dose of corticosteroids and/or have no requirement for anticonvulsants for 5 days prior to the baseline MRI and for 5 days prior to initiating brigatinib.
Exclusion criteria
1. Received an investigational agent ≤ 14 days prior to initiating brigatinib. 2. Received systemic anticancer therapy (including monoclonal antibodies and irreversible TKIs such as afatinib or dacomitinib) or radiation therapy ≤ 14 days prior to initiating brigatinib. a. Except for a reversible TKI (ie, erlotinib or gefitinib) or crizotinib, which are allowed up to 72 hours prior to initiating brigatinib, provided that the participant is free of treatment-related toxicity that might confound the safety evaluation of brigatinib. 3. Received any prior agents targeted against ALK, with the exception of crizotinib, or received more than 1 prior EGFR TKI. a. Re-challenge with the same TKI is allowed. 4. Major surgery within 28 days prior to initiating brigatinib. 5. Brain metastases that are neurologically unstable or require anticonvulsants or an increasing dose of corticosteroids. 1. Participants with previously treated brain metastases without evidence of disease or recurrence are allowed for cohorts 1-4. 2. Participants with evaluable but non-measurable, active brain lesions who otherwise meet the criteria for cohort 5 for CNS disease can be enrolled in other cohorts. 6. Significant uncontrolled or active cardiovascular disease. 7. Uncontrolled hypertension (diastolic blood pressure \[BP\] \> 100 mm Hg; systolic \> 150 mm Hg). 8. Prolonged QT interval, or being treated with medications known to cause Torsades de Pointes. 9. History or presence of pulmonary interstitial disease or drug-related pneumonitis. 10. Ongoing or active infection. The requirement for intravenous (IV) antibiotics is considered active infection. 11. Known history of human immunodeficiency virus (HIV). Testing is not required in the absence of history. 12. Pregnant or breastfeeding. 13. Malabsorption syndrome or other gastrointestinal illness that could affect oral absorption of brigatinib. 14. Any condition or illness that, in the opinion of the Investigator, would compromise participant safety or interfere with the evaluation of the safety of the drug. 15. Leptomeningeal carcinomatosis and spinal cord compression. In the case of suspected meningeal involvement, a negative lumbar puncture prior to study entry is required.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Recommended Phase 2 Dose (RP2D) of Brigatinib | 28 days | The RP2D is the maximum tolerated dose (MTD) or less. The MTD is defined as the dose range at which ≤ 1 of 6 evaluable participants experience dose limiting toxicities (DLT) within the first 28 days of treatment (end of Cycle 1). |
| Objective Response Rate (ORR) | From Screening and at 8-week intervals thereafter up to end of the study (up to 8.4 years) | ORR assessed by the investigator, is defined as the percentage of the participants with complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid tumors (RECIST) v1.1 after the initiation of study treatment. CR for target lesion: disappearance of all extranodal lesions and all pathological lymph nodes must have decreased to \<10 mm in short axis. CR for non-target lesion: Disappearance of all extranodal non-target lesions, all lymph nodes must be non-pathological in size (\<10mm short axis) and normalization of tumor marker level. PR: at least a 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline sum diameters. Crzb=Crizotinib. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Dose Limiting Toxicities (DLTs) Assessed in Dose Escalation Phase of the Study | Up to Cycle 1 (28 days) | DLT include any toxicity that is possibly, probably, or definitely drug-related. Toxicity grades will be defined by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v 4.0. DLTs are defined by the following: A) Non-hematologic toxicities: Any grade ≥3 non-hematologic toxicity, with the exception of self-limiting or medically controllable toxicities (eg, nausea, vomiting, fatigue, electrolyte disturbances, hypersensitivity reactions) lasting \< 3 days, and excluding alopecia. B) Hematologic toxicities: Febrile neutropenia not related to underlying disease (fever, \> 101°F; ANC\<500); Prolonged grade 4 neutropenia (\> 7 days); Neutropenic infection: ≥ grade 3 neutropenia with ≥ grade 3 infection; Thrombocytopenia ≥ grade 3 with bleeding or grade 4 lasting ≥ 7 days. C) Missed ≥ 25% of planned doses of brigatinib over 28 days due to treatment-related AEs in the first cycle. |
| Cmax: Maximum Observed Plasma Concentration for Brigatinib at Cycle 1 Day 1 | Cycle 1 (28-days cycle): Day 1 | — |
| Cmax: Maximum Observed Plasma Concentration for Brigatinib at Cycle 2 Day 1 | Cycle 2 (28-days cycle): Day 1 | — |
| Tmax: Time to Reach the Maximum Observed Plasma Concentration (Cmax) for Brigatinib at Cycle 1 Day 1 | Cycle 1 (28-days cycle): Day 1 | — |
| Tmax: Time to Reach the Maximum Observed Plasma Concentration (Cmax) for Brigatinib at Cycle 2 Day 1 | Cycle 2 (28-days cycle): Day 1 | — |
| AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Post-dose for Brigatinib at Cycle 1 Day 1 | Cycle 1 (28-days cycle): Day 1 multiple time points (up to 24 hours) post-dose | — |
| AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Post-dose for Brigatinib at Cycle 2 Day 1 | Cycle 2 (28-days cycle): Day 1 multiple time points (up to 24 hours) post-dose | — |
| Number of Participants Who Had at Least One Treatment-Emergent Adverse Event (TEAE) | From first dose of study drug up to 30 days following the last dose of the study treatment or the investigator/participant decision to discontinue treatment, whichever occurs first (approximately up to 7.4 years) | An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. |
| Best Overall Response | Screening and at 8-week intervals thereafter up to end of the study (up to 8.4 years) | Best overall response is defined as percentage of participants with CR, PR, stable disease (SD) or progressive disease (PD) as per of RECIST v1.1 as evaluated by investigator. CR for target lesion: disappearance of all extranodal lesions and all pathological lymph nodes must have decreased to \<10 mm in short axis. CR for non-target lesion: disappearance of all extranodal non-target lesions, all lymph nodes must be non-pathological in size (\<10mm short axis) and normalization of tumor marker level. PR: at least a 30% decrease in the SLD of target lesions, taking as reference the baseline sum diameters. Disease progression for target lesion: SLD increased by at least 20% from smallest value on study and SLD must also demonstrate an absolute increase of at least 5 mm or development of any new lesion. PD for non-target lesion: unequivocal progression of existing non-target lesions. SD for neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. |
| Duration of Response | Screening and at 8-week intervals thereafter up to end of the study (up to 8.4 years) | Duration of response is defined as time interval from time that measurement criteria are first met for CR/PR (whichever is first recorded) until first date that progressive disease is objectively documented or death due to any cause. Participants who did not progress nor die were censored at last valid response assessment.CR for target lesion: disappearance of all extranodal lesions and all pathological lymph nodes must have decreased to \<10 mm in short axis.CR for non-target lesion:disappearance of all extranodal non-target lesions,all lymph nodes must be non-pathological in size(\<10mm short axis) and normalization of tumor marker level.PR:at least a 30% decrease in SLD of target lesions.PD for target lesion:SLD increased by at least 20% from smallest value and must also demonstrate an absolute increase of \>=5 mm or development of any new lesion.PD for non-target lesion:unequivocal progression of existing non-target lesions.Duration of response calculated by Kaplan-Meier estimation. |
| Progression Free Survival (PFS) | Screening and at 8-week intervals thereafter up to end of the study (up to 8.4 years) | PFS is defined as the time interval from the date of the first dose of the study treatment until the first date at which disease progression is objectively documented, or death due to any cause, whichever occurs first. Disease progression for target lesion: SLD increased by at least 20% from the smallest value on study (including baseline, if that is the smallest) and SLD must also demonstrate an absolute increase of at least 5 mm or development of any new lesion. Disease progression for non-target lesion: Unequivocal progression of existing non-target lesions. (Subjective judgment by experienced reader). |
| Overall Survival (OS) | Screening and at 8-week intervals thereafter up to end of the study (up to 8.4 years) | OS is defined as the time interval from the date of the first dose of the study treatment until death due to any cause. |
| Intracranial Objective Response Rate | Screening and at 8-week intervals thereafter (approximately up to 50 months) | Intracranial objective response rate is defined as the percentage of the participants with CR or PR in the intracranial CNS per modification of RECIST v1.1 after the initiation of study drug. CR for target lesion: disappearance of all extranodal lesions. CR for non-target lesion: disappearance of all extranodal non-target lesions and normalization of tumor marker level. PR: at least a 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline sum diameters. |
| Duration of Intracranial Response | Screening and at 8-week intervals thereafter (approximately up to 50 months) | Intracranial duration of response is defined as the time interval from the time that the measurement criteria are first met for CR/PR in brain metastases (whichever is first recorded) until the first date that progressive disease is objectively documented or death due to any cause. Participants who did not progress nor die were censored at the last valid response assessment. Duration intracranial of response was calculated by Kaplan-Meier estimation. |
| Intracranial Progression Free Survival (PFS) | Screening and at 8-week intervals thereafter (approximately up to 50 months) | PFS is defined as the time interval from the date of the first dose of the study treatment until the first date at which disease progression in brain, or death due to any cause, whichever occurs first. Intracranial PFS was calculated by Kaplan-Meier estimation. |
| T1/2: Terminal Phase Elimination Half-life for Brigatinib at Cycle 2 Day 1 | Cycle 2 (28-days cycle): Day 1 | — |
| Maximum Tolerated Dose (MTD) Assessed in Dose Escalation Phase of the Study | Up to Cycle 1 (28 days) | The MTD is defined as the highest dose at which ≤ 1 of 6 evaluable participants experience a DLT within the first 28 days of treatment (end of Cycle 1). |
Participant flow
Recruitment details
Participants took part in the study at 9 investigative sites in the United States and Spain from 20 September 2011 to 18 February 2020.
Pre-assignment details
Participants with advanced malignancies, all histologies other than leukemia were enrolled in dose-escalation and participants with non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) rearrangements were enrolled in dose expansion phase. Participants received brigatinib 30 mg - 300 mg, tablets, orally once daily or twice daily.
Participants by arm
| Arm | Count |
|---|---|
| Brigatinib 30 mg QD/60 mg QD Brigatinib 30 mg/60 mg, tablets, orally, QD in each cycle of 28 days (Approximately up to 7.3 years). | 6 |
| Brigatinib 90 mg QD Brigatinib 90 mg, tablets, orally, QD in each cycle of 28 days (Approximately up to 7.3 years). | 18 |
| Brigatinib 120 mg QD/60 mg BID Brigatinib 120 mg, once daily or 60 mg, BID, tablets, orally, in each cycle of 28 days (Approximately up to 7.3 years). | 18 |
| Brigatinib 90 mg QD-180 mg QD Brigatinib 90 mg, tablets, orally, once daily for 7 days followed by brigatinib 180 mg, orally QD in Cycle 1 of 28 days followed by brigatinib 180 mg, orally QD in cycle 2 and onward cycles of 28 days (Approximately up to 7.3 years). | 32 |
| Brigatinib 180 mg QD/90 mg BID Brigatinib 180 mg, once daily or 90 mg, BID, tablets, orally in each cycle of 28 days (Approximately up to 7.3 years). | 48 |
| Brigatinib 240 mg QD/120 mg BID/300 mg QD Brigatinib 240 mg, QD or 120 mg, BID or 300 mg once daily, tablets, orally, in each cycle of 28 days (Approximately up to 7.3 years). | 15 |
| Total | 137 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 |
|---|---|---|---|---|---|---|---|
| Overall Study | Adverse Event | 0 | 3 | 2 | 3 | 4 | 4 |
| Overall Study | Clinical Progressive Disease | 2 | 2 | 0 | 3 | 4 | 2 |
| Overall Study | Death | 0 | 2 | 0 | 0 | 7 | 1 |
| Overall Study | Documented Progressive Disease | 4 | 7 | 14 | 15 | 24 | 5 |
| Overall Study | Physician Decision | 0 | 1 | 0 | 4 | 1 | 0 |
| Overall Study | Protocol Violation | 0 | 0 | 0 | 1 | 0 | 0 |
| Overall Study | Reason not Specified | 0 | 1 | 0 | 3 | 2 | 1 |
| Overall Study | Site Terminated by Sponsor | 0 | 1 | 2 | 3 | 4 | 1 |
| Overall Study | Withdrawal by Subject | 0 | 1 | 0 | 0 | 2 | 1 |
Baseline characteristics
| Characteristic | Brigatinib 30 mg QD/60 mg QD | Brigatinib 90 mg QD | Brigatinib 120 mg QD/60 mg BID | Brigatinib 90 mg QD-180 mg QD | Brigatinib 180 mg QD/90 mg BID | Brigatinib 240 mg QD/120 mg BID/300 mg QD | Total |
|---|---|---|---|---|---|---|---|
| Age, Continuous | 66.8 years STANDARD_DEVIATION 9.3 | 57.9 years STANDARD_DEVIATION 12.93 | 57.8 years STANDARD_DEVIATION 10.91 | 55.7 years STANDARD_DEVIATION 11.41 | 53.9 years STANDARD_DEVIATION 11.1 | 58.5 years STANDARD_DEVIATION 15.6 | 56.4 years STANDARD_DEVIATION 12.02 |
| Age, Customized Adults [18-64 years] | 2 Participants | 11 Participants | 12 Participants | 25 Participants | 39 Participants | 9 Participants | 98 Participants |
| Age, Customized From 65 to 84 years | 4 Participants | 7 Participants | 6 Participants | 7 Participants | 9 Participants | 6 Participants | 39 Participants |
| Eastern Cooperative Oncology Group (ECOG) Performance Score 0 | 0 Participants | 3 Participants | 3 Participants | 13 Participants | 13 Participants | 2 Participants | 34 Participants |
| Eastern Cooperative Oncology Group (ECOG) Performance Score 1 | 6 Participants | 15 Participants | 15 Participants | 19 Participants | 33 Participants | 13 Participants | 101 Participants |
| Eastern Cooperative Oncology Group (ECOG) Performance Score 2 | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 0 Participants | 2 Participants |
| Number of Participants with Mutation Types Anaplastic Lymphoma Kinase (ALK+) | 1 Participants | 16 Participants | 6 Participants | 29 Participants | 27 Participants | 5 Participants | 84 Participants |
| Number of Participants with Mutation Types Epidermal Growth Factor Receptor (EGFRm) | 2 Participants | 1 Participants | 10 Participants | 3 Participants | 18 Participants | 9 Participants | 43 Participants |
| Number of Participants with Mutation Types Other | 3 Participants | 1 Participants | 2 Participants | 0 Participants | 0 Participants | 0 Participants | 6 Participants |
| Number of Participants with Mutation Types ROS Proto-oncogene 1 (ROS1+) | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 3 Participants | 1 Participants | 4 Participants |
| Participants with Diagnosis of Cancer Type NSCLC | 3 Participants | 16 Participants | 18 Participants | 31 Participants | 45 Participants | 15 Participants | 128 Participants |
| Participants with Diagnosis of Cancer Type Other | 3 Participants | 2 Participants | 0 Participants | 1 Participants | 3 Participants | 0 Participants | 9 Participants |
| Participants with Prior Chemotherapy Regimen 0 | 0 Participants | 2 Participants | 7 Participants | 12 Participants | 12 Participants | 3 Participants | 36 Participants |
| Participants with Prior Chemotherapy Regimen 1 | 3 Participants | 4 Participants | 3 Participants | 6 Participants | 17 Participants | 2 Participants | 35 Participants |
| Participants with Prior Chemotherapy Regimen 2 | 0 Participants | 9 Participants | 4 Participants | 8 Participants | 10 Participants | 5 Participants | 36 Participants |
| Participants with Prior Chemotherapy Regimen > 2 | 3 Participants | 3 Participants | 4 Participants | 6 Participants | 9 Participants | 5 Participants | 30 Participants |
| Participants with Prior Radiotherapy to Brain No | 6 Participants | 13 Participants | 17 Participants | 24 Participants | 36 Participants | 14 Participants | 110 Participants |
| Participants with Prior Radiotherapy to Brain Yes | 0 Participants | 5 Participants | 1 Participants | 8 Participants | 12 Participants | 1 Participants | 27 Participants |
| Race/Ethnicity, Customized American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 2 Participants |
| Race/Ethnicity, Customized Asian | 0 Participants | 4 Participants | 3 Participants | 3 Participants | 5 Participants | 2 Participants | 17 Participants |
| Race/Ethnicity, Customized Black or African American | 0 Participants | 1 Participants | 2 Participants | 0 Participants | 1 Participants | 1 Participants | 5 Participants |
| Race/Ethnicity, Customized Hispanic or Latino | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 3 Participants |
| Race/Ethnicity, Customized Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Not Hispanic or Latino | 5 Participants | 18 Participants | 18 Participants | 31 Participants | 47 Participants | 15 Participants | 134 Participants |
| Race/Ethnicity, Customized Other | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Unknown | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized White | 6 Participants | 13 Participants | 13 Participants | 27 Participants | 39 Participants | 12 Participants | 110 Participants |
| Region of Enrollment Spain | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 7 Participants | 0 Participants | 7 Participants |
| Region of Enrollment United States | 6 Participants | 18 Participants | 18 Participants | 32 Participants | 41 Participants | 15 Participants | 130 Participants |
| Sex: Female, Male Female | 3 Participants | 12 Participants | 13 Participants | 14 Participants | 29 Participants | 8 Participants | 79 Participants |
| Sex: Female, Male Male | 3 Participants | 6 Participants | 5 Participants | 18 Participants | 19 Participants | 7 Participants | 58 Participants |
| Time Since Diagnosis of Cancer | 2.48 years STANDARD_DEVIATION 3.303 | 3.33 years STANDARD_DEVIATION 2.184 | 2.41 years STANDARD_DEVIATION 1.346 | 3.19 years STANDARD_DEVIATION 2.726 | 2.77 years STANDARD_DEVIATION 2.053 | 3.27 years STANDARD_DEVIATION 1.913 | 2.93 years STANDARD_DEVIATION 2.192 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk |
|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 6 / 6 | 11 / 18 | 12 / 18 | 17 / 32 | 25 / 48 | 11 / 15 |
| other Total, other adverse events | 6 / 6 | 17 / 18 | 17 / 18 | 31 / 32 | 45 / 48 | 15 / 15 |
| serious Total, serious adverse events | 1 / 6 | 10 / 18 | 10 / 18 | 14 / 32 | 30 / 48 | 11 / 15 |
Outcome results
Primary
Objective Response Rate (ORR)
ORR assessed by the investigator, is defined as the percentage of the participants with complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid tumors (RECIST) v1.1 after the initiation of study treatment. CR for target lesion: disappearance of all extranodal lesions and all pathological lymph nodes must have decreased to \<10 mm in short axis. CR for non-target lesion: Disappearance of all extranodal non-target lesions, all lymph nodes must be non-pathological in size (\<10mm short axis) and normalization of tumor marker level. PR: at least a 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline sum diameters. Crzb=Crizotinib.
Time frame: From Screening and at 8-week intervals thereafter up to end of the study (up to 8.4 years)
Population: Full analysis set (FAS) included all participants who received at least one dose of study drug. Participants with anaplastic lymphoma kinase (ALK) and non-small cell lung cancer (NSCLC) were evaluated for this outcome measure. Number analyzed is the number of participants with data evaluable for specific category.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Brigatinib | Objective Response Rate (ORR) | With Prior Treatment with Crizotinib | 0 percentage of participants |
| Brigatinib 90 mg QD | Objective Response Rate (ORR) | Without Prior Treatment with Crizotinib | 100.0 percentage of participants |
| Brigatinib 90 mg QD | Objective Response Rate (ORR) | With Prior Treatment with Crizotinib | 53.8 percentage of participants |
| Brigatinib 120 mg QD/60 mg BID | Objective Response Rate (ORR) | With Prior Treatment with Crizotinib | 60.0 percentage of participants |
| Brigatinib 120 mg QD/60 mg BID | Objective Response Rate (ORR) | Without Prior Treatment with Crizotinib | 100.0 percentage of participants |
| Brigatinib 90 mg QD-180 mg QD | Objective Response Rate (ORR) | Without Prior Treatment with Crizotinib | 100.0 percentage of participants |
| Brigatinib 90 mg QD-180 mg QD | Objective Response Rate (ORR) | With Prior Treatment with Crizotinib | 76.0 percentage of participants |
| Brigatinib 180 mg QD/90 mg BID | Objective Response Rate (ORR) | With Prior Treatment with Crizotinib | 65.2 percentage of participants |
| Brigatinib 180 mg QD/90 mg BID | Objective Response Rate (ORR) | Without Prior Treatment with Crizotinib | 100.0 percentage of participants |
| Brigatinib 240 mg QD/120 mg BID/300 mg QD | Objective Response Rate (ORR) | Without Prior Treatment with Crizotinib | 100.0 percentage of participants |
| Brigatinib 240 mg QD/120 mg BID/300 mg QD | Objective Response Rate (ORR) | With Prior Treatment with Crizotinib | 25.0 percentage of participants |
Primary
Recommended Phase 2 Dose (RP2D) of Brigatinib
The RP2D is the maximum tolerated dose (MTD) or less. The MTD is defined as the dose range at which ≤ 1 of 6 evaluable participants experience dose limiting toxicities (DLT) within the first 28 days of treatment (end of Cycle 1).
Time frame: 28 days
Population: Safety population included all enrolled participants who received at least one dose of study drug.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Brigatinib | Recommended Phase 2 Dose (RP2D) of Brigatinib | NA mg |
Secondary
AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Post-dose for Brigatinib at Cycle 1 Day 1
Time frame: Cycle 1 (28-days cycle): Day 1 multiple time points (up to 24 hours) post-dose
Population: Analysis was performed on all enrolled participants in the study who received at least one dose of brigatinib. Here, number of participants analyzed is the participants who were evaluable for this outcome measure. Participants of brigatinib 90 mg QD-180 mg QD arm were included as per treatment received at each time point.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Brigatinib | AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Post-dose for Brigatinib at Cycle 1 Day 1 | 1320.9 h*ng/mL | Standard Deviation 576.29 |
| Brigatinib 90 mg QD | AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Post-dose for Brigatinib at Cycle 1 Day 1 | 3900 h*ng/mL | Standard Deviation 430.31 |
| Brigatinib 120 mg QD/60 mg BID | AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Post-dose for Brigatinib at Cycle 1 Day 1 | 5710.1 h*ng/mL | Standard Deviation 3268.4 |
| Brigatinib 90 mg QD-180 mg QD | AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Post-dose for Brigatinib at Cycle 1 Day 1 | 9895.5 h*ng/mL | Standard Deviation 11772 |
| Brigatinib 180 mg QD/90 mg BID | AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Post-dose for Brigatinib at Cycle 1 Day 1 | 13204 h*ng/mL | Standard Deviation 6306.9 |
| Brigatinib 240 mg QD/120 mg BID/300 mg QD | AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Post-dose for Brigatinib at Cycle 1 Day 1 | 16800 h*ng/mL | Standard Deviation 7571.1 |
| Brigatinib 300 mg | AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Post-dose for Brigatinib at Cycle 1 Day 1 | 12356 h*ng/mL | Standard Deviation 5869 |
Secondary
AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Post-dose for Brigatinib at Cycle 2 Day 1
Time frame: Cycle 2 (28-days cycle): Day 1 multiple time points (up to 24 hours) post-dose
Population: Analysis was performed on all enrolled participants in the study who received at least one dose of brigatinib. Here, number of participants analyzed is the participants with data available for analyses for this outcome measure. Participants of brigatinib 90 mg QD-180 mg QD arm were included as per treatment received at each time point.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Brigatinib | AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Post-dose for Brigatinib at Cycle 2 Day 1 | 2689.0 h*ng/mL | Standard Deviation 1145.5 |
| Brigatinib 90 mg QD | AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Post-dose for Brigatinib at Cycle 2 Day 1 | 5069.0 h*ng/mL | Standard Deviation 1664.7 |
| Brigatinib 120 mg QD/60 mg BID | AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Post-dose for Brigatinib at Cycle 2 Day 1 | 9142.1 h*ng/mL | Standard Deviation 4076.7 |
| Brigatinib 90 mg QD-180 mg QD | AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Post-dose for Brigatinib at Cycle 2 Day 1 | 13888 h*ng/mL | Standard Deviation 7011.4 |
| Brigatinib 180 mg QD/90 mg BID | AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Post-dose for Brigatinib at Cycle 2 Day 1 | 23478 h*ng/mL | Standard Deviation 14463 |
| Brigatinib 240 mg QD/120 mg BID/300 mg QD | AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Post-dose for Brigatinib at Cycle 2 Day 1 | 30117 h*ng/mL | Standard Deviation 19921 |
Secondary
Best Overall Response
Best overall response is defined as percentage of participants with CR, PR, stable disease (SD) or progressive disease (PD) as per of RECIST v1.1 as evaluated by investigator. CR for target lesion: disappearance of all extranodal lesions and all pathological lymph nodes must have decreased to \<10 mm in short axis. CR for non-target lesion: disappearance of all extranodal non-target lesions, all lymph nodes must be non-pathological in size (\<10mm short axis) and normalization of tumor marker level. PR: at least a 30% decrease in the SLD of target lesions, taking as reference the baseline sum diameters. Disease progression for target lesion: SLD increased by at least 20% from smallest value on study and SLD must also demonstrate an absolute increase of at least 5 mm or development of any new lesion. PD for non-target lesion: unequivocal progression of existing non-target lesions. SD for neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
Time frame: Screening and at 8-week intervals thereafter up to end of the study (up to 8.4 years)
Population: Full analysis set included all participants who received at least one dose of study drug. Participants with ALK and NSCLC were evaluated for this outcome measure. Number analyzed is the number of participants with data evaluable for specific category.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Brigatinib | Best Overall Response | With Prior Treatment with Crizotinib: Stable Disease | 100.0 percentage of participants |
| Brigatinib | Best Overall Response | With Prior Treatment with Crizotinib: Complete Response | 0.0 percentage of participants |
| Brigatinib | Best Overall Response | With Prior Treatment with Crizotinib: Progressive Disease | 0.0 percentage of participants |
| Brigatinib | Best Overall Response | With Prior Treatment with Crizotinib: Partial Response | 0.0 percentage of participants |
| Brigatinib 90 mg QD | Best Overall Response | Without Prior Treatment with Crizotinib: Complete Response | 0.0 percentage of participants |
| Brigatinib 90 mg QD | Best Overall Response | With Prior Treatment with Crizotinib: Partial Response | 53.8 percentage of participants |
| Brigatinib 90 mg QD | Best Overall Response | With Prior Treatment with Crizotinib: Stable Disease | 23.1 percentage of participants |
| Brigatinib 90 mg QD | Best Overall Response | With Prior Treatment with Crizotinib: Progressive Disease | 0.0 percentage of participants |
| Brigatinib 90 mg QD | Best Overall Response | Without Prior Treatment with Crizotinib: Stable Disease | 0.0 percentage of participants |
| Brigatinib 90 mg QD | Best Overall Response | Without Prior Treatment with Crizotinib: Partial Response | 100.0 percentage of participants |
| Brigatinib 90 mg QD | Best Overall Response | With Prior Treatment with Crizotinib: Complete Response | 0.0 percentage of participants |
| Brigatinib 90 mg QD | Best Overall Response | Without Prior Treatment with Crizotinib: Progressive Disease | 0.0 percentage of participants |
| Brigatinib 120 mg QD/60 mg BID | Best Overall Response | With Prior Treatment with Crizotinib: Complete Response | 0.0 percentage of participants |
| Brigatinib 120 mg QD/60 mg BID | Best Overall Response | Without Prior Treatment with Crizotinib: Partial Response | 0.0 percentage of participants |
| Brigatinib 120 mg QD/60 mg BID | Best Overall Response | With Prior Treatment with Crizotinib: Stable Disease | 0.0 percentage of participants |
| Brigatinib 120 mg QD/60 mg BID | Best Overall Response | Without Prior Treatment with Crizotinib: Stable Disease | 0.0 percentage of participants |
| Brigatinib 120 mg QD/60 mg BID | Best Overall Response | Without Prior Treatment with Crizotinib: Complete Response | 100.0 percentage of participants |
| Brigatinib 120 mg QD/60 mg BID | Best Overall Response | With Prior Treatment with Crizotinib: Partial Response | 60.0 percentage of participants |
| Brigatinib 120 mg QD/60 mg BID | Best Overall Response | With Prior Treatment with Crizotinib: Progressive Disease | 0.0 percentage of participants |
| Brigatinib 120 mg QD/60 mg BID | Best Overall Response | Without Prior Treatment with Crizotinib: Progressive Disease | 0.0 percentage of participants |
| Brigatinib 90 mg QD-180 mg QD | Best Overall Response | With Prior Treatment with Crizotinib: Complete Response | 12.0 percentage of participants |
| Brigatinib 90 mg QD-180 mg QD | Best Overall Response | Without Prior Treatment with Crizotinib: Complete Response | 33.3 percentage of participants |
| Brigatinib 90 mg QD-180 mg QD | Best Overall Response | With Prior Treatment with Crizotinib: Stable Disease | 12.0 percentage of participants |
| Brigatinib 90 mg QD-180 mg QD | Best Overall Response | Without Prior Treatment with Crizotinib: Progressive Disease | 0.0 percentage of participants |
| Brigatinib 90 mg QD-180 mg QD | Best Overall Response | Without Prior Treatment with Crizotinib: Partial Response | 66.7 percentage of participants |
| Brigatinib 90 mg QD-180 mg QD | Best Overall Response | With Prior Treatment with Crizotinib: Partial Response | 64.0 percentage of participants |
| Brigatinib 90 mg QD-180 mg QD | Best Overall Response | With Prior Treatment with Crizotinib: Progressive Disease | 8.0 percentage of participants |
| Brigatinib 90 mg QD-180 mg QD | Best Overall Response | Without Prior Treatment with Crizotinib: Stable Disease | 0.0 percentage of participants |
| Brigatinib 180 mg QD/90 mg BID | Best Overall Response | Without Prior Treatment with Crizotinib: Progressive Disease | 0.0 percentage of participants |
| Brigatinib 180 mg QD/90 mg BID | Best Overall Response | With Prior Treatment with Crizotinib: Partial Response | 56.5 percentage of participants |
| Brigatinib 180 mg QD/90 mg BID | Best Overall Response | With Prior Treatment with Crizotinib: Stable Disease | 13.0 percentage of participants |
| Brigatinib 180 mg QD/90 mg BID | Best Overall Response | Without Prior Treatment with Crizotinib: Partial Response | 100.0 percentage of participants |
| Brigatinib 180 mg QD/90 mg BID | Best Overall Response | Without Prior Treatment with Crizotinib: Stable Disease | 0.0 percentage of participants |
| Brigatinib 180 mg QD/90 mg BID | Best Overall Response | Without Prior Treatment with Crizotinib: Complete Response | 0.0 percentage of participants |
| Brigatinib 180 mg QD/90 mg BID | Best Overall Response | With Prior Treatment with Crizotinib: Complete Response | 8.7 percentage of participants |
| Brigatinib 180 mg QD/90 mg BID | Best Overall Response | With Prior Treatment with Crizotinib: Progressive Disease | 21.7 percentage of participants |
| Brigatinib 240 mg QD/120 mg BID/300 mg QD | Best Overall Response | With Prior Treatment with Crizotinib: Progressive Disease | 0.0 percentage of participants |
| Brigatinib 240 mg QD/120 mg BID/300 mg QD | Best Overall Response | With Prior Treatment with Crizotinib: Partial Response | 25.0 percentage of participants |
| Brigatinib 240 mg QD/120 mg BID/300 mg QD | Best Overall Response | With Prior Treatment with Crizotinib: Stable Disease | 75.0 percentage of participants |
| Brigatinib 240 mg QD/120 mg BID/300 mg QD | Best Overall Response | Without Prior Treatment with Crizotinib: Stable Disease | 0.0 percentage of participants |
| Brigatinib 240 mg QD/120 mg BID/300 mg QD | Best Overall Response | With Prior Treatment with Crizotinib: Complete Response | 0.0 percentage of participants |
| Brigatinib 240 mg QD/120 mg BID/300 mg QD | Best Overall Response | Without Prior Treatment with Crizotinib: Progressive Disease | 0.0 percentage of participants |
| Brigatinib 240 mg QD/120 mg BID/300 mg QD | Best Overall Response | Without Prior Treatment with Crizotinib: Complete Response | 100.0 percentage of participants |
| Brigatinib 240 mg QD/120 mg BID/300 mg QD | Best Overall Response | Without Prior Treatment with Crizotinib: Partial Response | 0.0 percentage of participants |
Secondary
Cmax: Maximum Observed Plasma Concentration for Brigatinib at Cycle 1 Day 1
Time frame: Cycle 1 (28-days cycle): Day 1
Population: Analysis was performed on all enrolled participants in the study who received at least one dose of brigatinib. Here number of participants analyzed is the participants who were evaluable for this outcome measure. Participants of brigatinib 90 mg QD-180 mg QD arm were included as per treatment received at each time point.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Brigatinib | Cmax: Maximum Observed Plasma Concentration for Brigatinib at Cycle 1 Day 1 | 125.6 ng/mL | Standard Deviation 41.07 |
| Brigatinib 90 mg QD | Cmax: Maximum Observed Plasma Concentration for Brigatinib at Cycle 1 Day 1 | 406.3 ng/mL | Standard Deviation 102 |
| Brigatinib 120 mg QD/60 mg BID | Cmax: Maximum Observed Plasma Concentration for Brigatinib at Cycle 1 Day 1 | 493 ng/mL | Standard Deviation 289.5 |
| Brigatinib 90 mg QD-180 mg QD | Cmax: Maximum Observed Plasma Concentration for Brigatinib at Cycle 1 Day 1 | 793.7 ng/mL | Standard Deviation 828.7 |
| Brigatinib 180 mg QD/90 mg BID | Cmax: Maximum Observed Plasma Concentration for Brigatinib at Cycle 1 Day 1 | 1185 ng/mL | Standard Deviation 607.6 |
| Brigatinib 240 mg QD/120 mg BID/300 mg QD | Cmax: Maximum Observed Plasma Concentration for Brigatinib at Cycle 1 Day 1 | 1515 ng/mL | Standard Deviation 637.9 |
| Brigatinib 300 mg | Cmax: Maximum Observed Plasma Concentration for Brigatinib at Cycle 1 Day 1 | 895 ng/mL | Standard Deviation 487.9 |
Secondary
Cmax: Maximum Observed Plasma Concentration for Brigatinib at Cycle 2 Day 1
Time frame: Cycle 2 (28-days cycle): Day 1
Population: Analysis was performed on all enrolled participants in the study who received at least one dose of brigatinib. Here number of participants analyzed is the participants with data available for analysis for this outcome measure. Participants of brigatinib 90 mg QD-180 mg QD arm were included as per treatment received at each time point.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Brigatinib | Cmax: Maximum Observed Plasma Concentration for Brigatinib at Cycle 2 Day 1 | 249.50 ng/mL | Standard Deviation 167.58 |
| Brigatinib 90 mg QD | Cmax: Maximum Observed Plasma Concentration for Brigatinib at Cycle 2 Day 1 | 491.67 ng/mL | Standard Deviation 223.95 |
| Brigatinib 120 mg QD/60 mg BID | Cmax: Maximum Observed Plasma Concentration for Brigatinib at Cycle 2 Day 1 | 634.07 ng/mL | Standard Deviation 310.05 |
| Brigatinib 90 mg QD-180 mg QD | Cmax: Maximum Observed Plasma Concentration for Brigatinib at Cycle 2 Day 1 | 942.30 ng/mL | Standard Deviation 472.33 |
| Brigatinib 180 mg QD/90 mg BID | Cmax: Maximum Observed Plasma Concentration for Brigatinib at Cycle 2 Day 1 | 1694.3 ng/mL | Standard Deviation 1014.3 |
| Brigatinib 240 mg QD/120 mg BID/300 mg QD | Cmax: Maximum Observed Plasma Concentration for Brigatinib at Cycle 2 Day 1 | 2280.0 ng/mL | Standard Deviation 1308.5 |
Secondary
Duration of Intracranial Response
Intracranial duration of response is defined as the time interval from the time that the measurement criteria are first met for CR/PR in brain metastases (whichever is first recorded) until the first date that progressive disease is objectively documented or death due to any cause. Participants who did not progress nor die were censored at the last valid response assessment. Duration intracranial of response was calculated by Kaplan-Meier estimation.
Time frame: Screening and at 8-week intervals thereafter (approximately up to 50 months)
Population: Full analysis set. ALK+ NSCLC participants with measurable and non-measurable brain metastases at baseline were evaluated for this outcome measure.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Brigatinib 90 mg QD | Duration of Intracranial Response | 12.9 months |
| Brigatinib 120 mg QD/60 mg BID | Duration of Intracranial Response | 5.0 months |
| Brigatinib 90 mg QD-180 mg QD | Duration of Intracranial Response | 11.4 months |
| Brigatinib 180 mg QD/90 mg BID | Duration of Intracranial Response | 29.2 months |
| Brigatinib 240 mg QD/120 mg BID/300 mg QD | Duration of Intracranial Response | 11.3 months |
Secondary
Duration of Response
Duration of response is defined as time interval from time that measurement criteria are first met for CR/PR (whichever is first recorded) until first date that progressive disease is objectively documented or death due to any cause. Participants who did not progress nor die were censored at last valid response assessment.CR for target lesion: disappearance of all extranodal lesions and all pathological lymph nodes must have decreased to \<10 mm in short axis.CR for non-target lesion:disappearance of all extranodal non-target lesions,all lymph nodes must be non-pathological in size(\<10mm short axis) and normalization of tumor marker level.PR:at least a 30% decrease in SLD of target lesions.PD for target lesion:SLD increased by at least 20% from smallest value and must also demonstrate an absolute increase of \>=5 mm or development of any new lesion.PD for non-target lesion:unequivocal progression of existing non-target lesions.Duration of response calculated by Kaplan-Meier estimation.
Time frame: Screening and at 8-week intervals thereafter up to end of the study (up to 8.4 years)
Population: Full analysis set included all participants who received at least one dose of study drug. Participants who were responders among those who had ALK and NSCLC were evaluated for this outcome measure. Number analyzed is the number of participants with data evaluable for specific category.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Brigatinib 90 mg QD | Duration of Response | Without Prior Treatment with Crizotinib | 30.4 months |
| Brigatinib 90 mg QD | Duration of Response | With Prior Treatment with Crizotinib | 11.1 months |
| Brigatinib 120 mg QD/60 mg BID | Duration of Response | With Prior Treatment with Crizotinib | 4.0 months |
| Brigatinib 120 mg QD/60 mg BID | Duration of Response | Without Prior Treatment with Crizotinib | 60.3 months |
| Brigatinib 90 mg QD-180 mg QD | Duration of Response | Without Prior Treatment with Crizotinib | 52.0 months |
| Brigatinib 90 mg QD-180 mg QD | Duration of Response | With Prior Treatment with Crizotinib | 14.8 months |
| Brigatinib 180 mg QD/90 mg BID | Duration of Response | With Prior Treatment with Crizotinib | 20.4 months |
| Brigatinib 180 mg QD/90 mg BID | Duration of Response | Without Prior Treatment with Crizotinib | 20.8 months |
| Brigatinib 240 mg QD/120 mg BID/300 mg QD | Duration of Response | Without Prior Treatment with Crizotinib | NA months |
| Brigatinib 240 mg QD/120 mg BID/300 mg QD | Duration of Response | With Prior Treatment with Crizotinib | 29.7 months |
Secondary
Intracranial Objective Response Rate
Intracranial objective response rate is defined as the percentage of the participants with CR or PR in the intracranial CNS per modification of RECIST v1.1 after the initiation of study drug. CR for target lesion: disappearance of all extranodal lesions. CR for non-target lesion: disappearance of all extranodal non-target lesions and normalization of tumor marker level. PR: at least a 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline sum diameters.
Time frame: Screening and at 8-week intervals thereafter (approximately up to 50 months)
Population: Full analysis set. ALK+ NSCLC participants with measurable and non-measurable brain metastases at baseline were evaluated for this outcome measure. Here, number analyzed is the number of participants who were evaluable for specific category.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Brigatinib 90 mg QD | Intracranial Objective Response Rate | Only Non-Measurable Brain Metastases | 16.7 percentage of participants |
| Brigatinib 90 mg QD | Intracranial Objective Response Rate | Measurable Brain Metastases | 100 percentage of participants |
| Brigatinib 120 mg QD/60 mg BID | Intracranial Objective Response Rate | Only Non-Measurable Brain Metastases | 100 percentage of participants |
| Brigatinib 90 mg QD-180 mg QD | Intracranial Objective Response Rate | Measurable Brain Metastases | 80 percentage of participants |
| Brigatinib 90 mg QD-180 mg QD | Intracranial Objective Response Rate | Only Non-Measurable Brain Metastases | 46.2 percentage of participants |
| Brigatinib 180 mg QD/90 mg BID | Intracranial Objective Response Rate | Measurable Brain Metastases | 42.9 percentage of participants |
| Brigatinib 180 mg QD/90 mg BID | Intracranial Objective Response Rate | Only Non-Measurable Brain Metastases | 44.4 percentage of participants |
| Brigatinib 240 mg QD/120 mg BID/300 mg QD | Intracranial Objective Response Rate | Only Non-Measurable Brain Metastases | 50.0 percentage of participants |
| Brigatinib 240 mg QD/120 mg BID/300 mg QD | Intracranial Objective Response Rate | Measurable Brain Metastases | 100 percentage of participants |
Secondary
Intracranial Progression Free Survival (PFS)
PFS is defined as the time interval from the date of the first dose of the study treatment until the first date at which disease progression in brain, or death due to any cause, whichever occurs first. Intracranial PFS was calculated by Kaplan-Meier estimation.
Time frame: Screening and at 8-week intervals thereafter (approximately up to 50 months)
Population: Full analysis set. ALK+ NSCLC participants with measurable and non-measurable brain metastases at baseline were evaluated for this outcome measure.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Brigatinib 90 mg QD | Intracranial Progression Free Survival (PFS) | 36.8 months |
| Brigatinib 120 mg QD/60 mg BID | Intracranial Progression Free Survival (PFS) | 6.7 months |
| Brigatinib 90 mg QD-180 mg QD | Intracranial Progression Free Survival (PFS) | NA months |
| Brigatinib 180 mg QD/90 mg BID | Intracranial Progression Free Survival (PFS) | 14.4 months |
| Brigatinib 240 mg QD/120 mg BID/300 mg QD | Intracranial Progression Free Survival (PFS) | 7.3 months |
Secondary
Maximum Tolerated Dose (MTD) Assessed in Dose Escalation Phase of the Study
The MTD is defined as the highest dose at which ≤ 1 of 6 evaluable participants experience a DLT within the first 28 days of treatment (end of Cycle 1).
Time frame: Up to Cycle 1 (28 days)
Population: Safety population included all enrolled participants who received at least one dose of study drug. Participants enrolled in the dose escalation phase were included in the analysis.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Brigatinib | Maximum Tolerated Dose (MTD) Assessed in Dose Escalation Phase of the Study | NA mg |
Secondary
Number of Participants Who Had at Least One Treatment-Emergent Adverse Event (TEAE)
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
Time frame: From first dose of study drug up to 30 days following the last dose of the study treatment or the investigator/participant decision to discontinue treatment, whichever occurs first (approximately up to 7.4 years)
Population: Safety population included all enrolled participants who received at least one dose of study drug.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Brigatinib | Number of Participants Who Had at Least One Treatment-Emergent Adverse Event (TEAE) | 6 Participants |
| Brigatinib 90 mg QD | Number of Participants Who Had at Least One Treatment-Emergent Adverse Event (TEAE) | 18 Participants |
| Brigatinib 120 mg QD/60 mg BID | Number of Participants Who Had at Least One Treatment-Emergent Adverse Event (TEAE) | 18 Participants |
| Brigatinib 90 mg QD-180 mg QD | Number of Participants Who Had at Least One Treatment-Emergent Adverse Event (TEAE) | 32 Participants |
| Brigatinib 180 mg QD/90 mg BID | Number of Participants Who Had at Least One Treatment-Emergent Adverse Event (TEAE) | 48 Participants |
| Brigatinib 240 mg QD/120 mg BID/300 mg QD | Number of Participants Who Had at Least One Treatment-Emergent Adverse Event (TEAE) | 15 Participants |
Secondary
Number of Participants With Dose Limiting Toxicities (DLTs) Assessed in Dose Escalation Phase of the Study
DLT include any toxicity that is possibly, probably, or definitely drug-related. Toxicity grades will be defined by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v 4.0. DLTs are defined by the following: A) Non-hematologic toxicities: Any grade ≥3 non-hematologic toxicity, with the exception of self-limiting or medically controllable toxicities (eg, nausea, vomiting, fatigue, electrolyte disturbances, hypersensitivity reactions) lasting \< 3 days, and excluding alopecia. B) Hematologic toxicities: Febrile neutropenia not related to underlying disease (fever, \> 101°F; ANC\<500); Prolonged grade 4 neutropenia (\> 7 days); Neutropenic infection: ≥ grade 3 neutropenia with ≥ grade 3 infection; Thrombocytopenia ≥ grade 3 with bleeding or grade 4 lasting ≥ 7 days. C) Missed ≥ 25% of planned doses of brigatinib over 28 days due to treatment-related AEs in the first cycle.
Time frame: Up to Cycle 1 (28 days)
Population: DLT-evaluable population included participants who received ≥75% of planned study drug doses during Cycle 1.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Brigatinib | Number of Participants With Dose Limiting Toxicities (DLTs) Assessed in Dose Escalation Phase of the Study | 0 participants |
| Brigatinib 90 mg QD | Number of Participants With Dose Limiting Toxicities (DLTs) Assessed in Dose Escalation Phase of the Study | 0 participants |
| Brigatinib 120 mg QD/60 mg BID | Number of Participants With Dose Limiting Toxicities (DLTs) Assessed in Dose Escalation Phase of the Study | 0 participants |
| Brigatinib 90 mg QD-180 mg QD | Number of Participants With Dose Limiting Toxicities (DLTs) Assessed in Dose Escalation Phase of the Study | 0 participants |
| Brigatinib 180 mg QD/90 mg BID | Number of Participants With Dose Limiting Toxicities (DLTs) Assessed in Dose Escalation Phase of the Study | 0 participants |
| Brigatinib 240 mg QD/120 mg BID/300 mg QD | Number of Participants With Dose Limiting Toxicities (DLTs) Assessed in Dose Escalation Phase of the Study | 1 participants |
| Brigatinib 300 mg | Number of Participants With Dose Limiting Toxicities (DLTs) Assessed in Dose Escalation Phase of the Study | 1 participants |
Secondary
Overall Survival (OS)
OS is defined as the time interval from the date of the first dose of the study treatment until death due to any cause.
Time frame: Screening and at 8-week intervals thereafter up to end of the study (up to 8.4 years)
Population: Analysis was performed on all enrolled participants in the study who received at least one dose of brigatinib. Here, overall number of participants analyzed is the participants who were evaluable for this outcome measure.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Brigatinib | Overall Survival (OS) | 5.3 months |
| Brigatinib 90 mg QD | Overall Survival (OS) | 11.6 months |
| Brigatinib 120 mg QD/60 mg BID | Overall Survival (OS) | 7.3 months |
| Brigatinib 90 mg QD-180 mg QD | Overall Survival (OS) | 17.9 months |
| Brigatinib 180 mg QD/90 mg BID | Overall Survival (OS) | 7.3 months |
| Brigatinib 240 mg QD/120 mg BID/300 mg QD | Overall Survival (OS) | 8.3 months |
Secondary
Progression Free Survival (PFS)
PFS is defined as the time interval from the date of the first dose of the study treatment until the first date at which disease progression is objectively documented, or death due to any cause, whichever occurs first. Disease progression for target lesion: SLD increased by at least 20% from the smallest value on study (including baseline, if that is the smallest) and SLD must also demonstrate an absolute increase of at least 5 mm or development of any new lesion. Disease progression for non-target lesion: Unequivocal progression of existing non-target lesions. (Subjective judgment by experienced reader).
Time frame: Screening and at 8-week intervals thereafter up to end of the study (up to 8.4 years)
Population: Analysis was performed on all enrolled participants in the study who received at least one dose of brigatinib. Here, overall number of participants analyzed is the participants who were evaluable for this outcome measure.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Brigatinib | Progression Free Survival (PFS) | 1.8 months |
| Brigatinib 90 mg QD | Progression Free Survival (PFS) | 12.6 months |
| Brigatinib 120 mg QD/60 mg BID | Progression Free Survival (PFS) | 5.4 months |
| Brigatinib 90 mg QD-180 mg QD | Progression Free Survival (PFS) | 11.0 months |
| Brigatinib 180 mg QD/90 mg BID | Progression Free Survival (PFS) | 5.4 months |
| Brigatinib 240 mg QD/120 mg BID/300 mg QD | Progression Free Survival (PFS) | 5.4 months |
Secondary
T1/2: Terminal Phase Elimination Half-life for Brigatinib at Cycle 2 Day 1
Time frame: Cycle 2 (28-days cycle): Day 1
Population: Analysis was performed on all enrolled participants in the study who received at least one dose of brigatinib. Here, number of participants analyzed is the participants with data available for analyses for this outcome measure. Participants of brigatinib 90 mg QD-180 mg QD arm were included as per treatment received at each time point.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Brigatinib | T1/2: Terminal Phase Elimination Half-life for Brigatinib at Cycle 2 Day 1 | 31.55 hours | Standard Deviation 2.758 |
| Brigatinib 90 mg QD | T1/2: Terminal Phase Elimination Half-life for Brigatinib at Cycle 2 Day 1 | 30.93 hours | Standard Deviation 5.873 |
| Brigatinib 120 mg QD/60 mg BID | T1/2: Terminal Phase Elimination Half-life for Brigatinib at Cycle 2 Day 1 | 28.69 hours | Standard Deviation 10.06 |
| Brigatinib 90 mg QD-180 mg QD | T1/2: Terminal Phase Elimination Half-life for Brigatinib at Cycle 2 Day 1 | 25.52 hours | Standard Deviation 7.958 |
| Brigatinib 180 mg QD/90 mg BID | T1/2: Terminal Phase Elimination Half-life for Brigatinib at Cycle 2 Day 1 | 24.90 hours | Standard Deviation 7.437 |
| Brigatinib 240 mg QD/120 mg BID/300 mg QD | T1/2: Terminal Phase Elimination Half-life for Brigatinib at Cycle 2 Day 1 | 21.77 hours | Standard Deviation 4.007 |
Secondary
Tmax: Time to Reach the Maximum Observed Plasma Concentration (Cmax) for Brigatinib at Cycle 1 Day 1
Time frame: Cycle 1 (28-days cycle): Day 1
Population: Analysis was performed on all enrolled participants in the study who received at least one dose of brigatinib. Here, number of participants analyzed is the participants who were evaluable for this outcome measure. Participants of brigatinib 90 mg QD-180 mg QD arm were included as per treatment received at each time point.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Brigatinib | Tmax: Time to Reach the Maximum Observed Plasma Concentration (Cmax) for Brigatinib at Cycle 1 Day 1 | 3.9 hours |
| Brigatinib 90 mg QD | Tmax: Time to Reach the Maximum Observed Plasma Concentration (Cmax) for Brigatinib at Cycle 1 Day 1 | 1.0 hours |
| Brigatinib 120 mg QD/60 mg BID | Tmax: Time to Reach the Maximum Observed Plasma Concentration (Cmax) for Brigatinib at Cycle 1 Day 1 | 2.0 hours |
| Brigatinib 90 mg QD-180 mg QD | Tmax: Time to Reach the Maximum Observed Plasma Concentration (Cmax) for Brigatinib at Cycle 1 Day 1 | 2.0 hours |
| Brigatinib 180 mg QD/90 mg BID | Tmax: Time to Reach the Maximum Observed Plasma Concentration (Cmax) for Brigatinib at Cycle 1 Day 1 | 2.0 hours |
| Brigatinib 240 mg QD/120 mg BID/300 mg QD | Tmax: Time to Reach the Maximum Observed Plasma Concentration (Cmax) for Brigatinib at Cycle 1 Day 1 | 2.0 hours |
| Brigatinib 300 mg | Tmax: Time to Reach the Maximum Observed Plasma Concentration (Cmax) for Brigatinib at Cycle 1 Day 1 | 4.05 hours |
Secondary
Tmax: Time to Reach the Maximum Observed Plasma Concentration (Cmax) for Brigatinib at Cycle 2 Day 1
Time frame: Cycle 2 (28-days cycle): Day 1
Population: Analysis was performed on all enrolled participants in the study who received at least one dose of brigatinib. Here, number of participants analyzed is the participants with data available for analyses for this outcome measure. Participants of brigatinib 90 mg QD-180 mg QD arm were included as per treatment received at each time point.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Brigatinib | Tmax: Time to Reach the Maximum Observed Plasma Concentration (Cmax) for Brigatinib at Cycle 2 Day 1 | 2.49 hours |
| Brigatinib 90 mg QD | Tmax: Time to Reach the Maximum Observed Plasma Concentration (Cmax) for Brigatinib at Cycle 2 Day 1 | 1.00 hours |
| Brigatinib 120 mg QD/60 mg BID | Tmax: Time to Reach the Maximum Observed Plasma Concentration (Cmax) for Brigatinib at Cycle 2 Day 1 | 2.00 hours |
| Brigatinib 90 mg QD-180 mg QD | Tmax: Time to Reach the Maximum Observed Plasma Concentration (Cmax) for Brigatinib at Cycle 2 Day 1 | 3.00 hours |
| Brigatinib 180 mg QD/90 mg BID | Tmax: Time to Reach the Maximum Observed Plasma Concentration (Cmax) for Brigatinib at Cycle 2 Day 1 | 2.10 hours |
| Brigatinib 240 mg QD/120 mg BID/300 mg QD | Tmax: Time to Reach the Maximum Observed Plasma Concentration (Cmax) for Brigatinib at Cycle 2 Day 1 | 2.00 hours |